ArticleQuantitative imaging in medicine and surgery2025
Safety and efficacy of microwave ablation versus argon-helium cryoablation for the treatment of primary high-risk pulmonary nodules: a propensity score-matched study.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research status and trend of lung cancer ablation therapy: a bibliometric analysis from 2002 to 2025.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although microwave ablation (MWA) and cryoablation (CA) have shown promising clinical potential in treating pulmonary nodules, a direct comparative study of these two techniques for primary high-risk pulmonary nodules is still lacking. Therefore, this study aims to compare the safety and efficacy of MWA versus CA in patients with primary high-risk pulmonary nodules. Methods: This retrospective study analyzed 139 patients treated with either CA (n=31) or MWA (n=108) for 162 nodules between January 2019 and December 2023. Propensity score matching (PSM) was performed based on age, gender, and Charlson Comorbidity Index at a 1:2 ratio, resulting in 95 patients with 114 nodules. Outcomes evaluated included technical success, disease-free survival (DFS), overall survival (OS), and post-procedural complications. All procedures were computed tomography (CT)-guided, with follow-up CT scans at 1, 3, and 6 months, then every 6 months. Results: Both CA and MWA achieved 100% technical success. The median follow-up was 25 months. Local disease progression rates before matching were 11.43% (CA) and 6.30% (MWA), and after PSM, 12.12% and 7.41%, respectively, with no significant difference. All patients survived at the last follow-up. Post-PSM complication rates were similar (79.31% CA Conclusions: MWA and CA are comparably safe and effective minimally invasive alternatives for treating high-risk pulmonary nodules in patients unsuitable for surgery, with CA showing the advantage of reduced procedural pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.